Search research articles
Contact Us
Filters
Showing results (11-20 of 54) with videos related to
Page
of 6
Sort By:
The European Respiratory Journal
|
April 7, 2017
Molecular biomarkers for lung adenocarcinoma
Olivier Calvayrac, Anne Pradines, Elvire Pons, et al.
Cells
|
November 27, 2021
<i>STK11/LKB1</i> Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
Elvire Pons-Tostivint, Alexandre Lugat, Jean-François Fontenau, et al.
Respiratory Medicine and Research
|
June 6, 2024
Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient
Elvire Pons-Tostivint, Pauline Hulo, Christine Sagan, et al.
Targeted Oncology
|
June 2, 2024
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib
Thomas Papazyan, Marc G Denis, Christine Sagan, et al.
Bulletin Du Cancer
|
October 21, 2018
[Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations]
Marie Auvray, Camille Baylot, Félix Blanc-Durand, et al.
Frontiers in Oncology
|
July 12, 2021
Homozygous Co-Deletion of Type I Interferons and <i>CDKN2A</i> Genes in Thoracic Cancers: Potential Consequences for Therapy
Marion Grard, Camille Chatelain, Tiphaine Delaunay, et al.
Cancer Immunology, Immunotherapy : CII
|
August 26, 2025
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
Adrien Costantini, Paul Takam Kamga, Elvire Pons-Tostivint, et al.
Translational Lung Cancer Research
|
May 22, 2026
Methylated circulating tumor DNA: technical challenges and clinical applications in non-small cell lung cancer patients-a narrative review
Manon Robert, Chloé Sauzay, Sandrine Théoleyre, et al.
Bulletin Du Cancer
|
March 14, 2024
[National survey of Advanced Practice Nurses in oncology-haematology: Evaluation of activity and continuing education]
Elvire Pons-Tostivint, Laure De Decker, Gaëlle Haudebert, et al.
Current Oncology (Toronto, Ont.)
|
May 27, 2022
HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature
Laurent Mathiot, Guillaume Herbreteau, Siméon Robin, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 54) with videos related to
Sort By:
Page
of 6
The European Respiratory Journal
|
April 7, 2017
Molecular biomarkers for lung adenocarcinoma
Olivier Calvayrac, Anne Pradines, Elvire Pons, et al.
Cells
|
November 27, 2021
<i>STK11/LKB1</i> Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
Elvire Pons-Tostivint, Alexandre Lugat, Jean-François Fontenau, et al.
Respiratory Medicine and Research
|
June 6, 2024
Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient
Elvire Pons-Tostivint, Pauline Hulo, Christine Sagan, et al.
Targeted Oncology
|
June 2, 2024
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib
Thomas Papazyan, Marc G Denis, Christine Sagan, et al.
Bulletin Du Cancer
|
October 21, 2018
[Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations]
Marie Auvray, Camille Baylot, Félix Blanc-Durand, et al.
Frontiers in Oncology
|
July 12, 2021
Homozygous Co-Deletion of Type I Interferons and <i>CDKN2A</i> Genes in Thoracic Cancers: Potential Consequences for Therapy
Marion Grard, Camille Chatelain, Tiphaine Delaunay, et al.
Cancer Immunology, Immunotherapy : CII
|
August 26, 2025
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
Adrien Costantini, Paul Takam Kamga, Elvire Pons-Tostivint, et al.
Translational Lung Cancer Research
|
May 22, 2026
Methylated circulating tumor DNA: technical challenges and clinical applications in non-small cell lung cancer patients-a narrative review
Manon Robert, Chloé Sauzay, Sandrine Théoleyre, et al.
Bulletin Du Cancer
|
March 14, 2024
[National survey of Advanced Practice Nurses in oncology-haematology: Evaluation of activity and continuing education]
Elvire Pons-Tostivint, Laure De Decker, Gaëlle Haudebert, et al.
Current Oncology (Toronto, Ont.)
|
May 27, 2022
HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature
Laurent Mathiot, Guillaume Herbreteau, Siméon Robin, et al.
Page
of 6